HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

M Le Bars Selected Research

Fatigue

4/2008Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


M Le Bars Research Topics

Disease

5Pain (Aches)
04/2010 - 05/2000
4Rheumatoid Arthritis
03/2010 - 04/2008
2Osteoarthritis
04/2010 - 08/2004
2Knee Osteoarthritis
04/2010 - 08/2004
2Necrosis
11/2009 - 04/2008
1Synovitis
04/2010
1Fatigue
04/2008
1Inflammation (Inflammations)
08/2004
1Opioid-Related Disorders (Opiate Addiction)
05/2000
1Substance-Related Disorders (Drug Abuse)
05/2000

Drug/Important Bio-Agent (IBA)

4Abatacept (Orencia)FDA Link
03/2010 - 04/2008
2Acetaminophen (Paracetamol)FDA LinkGeneric
08/2004 - 01/2001
2Pharmaceutical PreparationsIBA
01/2001 - 05/2000
1vasectrin IIIIBA
04/2010
1C-Reactive ProteinIBA
04/2008
1ametantrone (HAQ)IBA
04/2008
1Opiate AlkaloidsIBA
05/2000
1Morphine (MS Contin)FDA LinkGeneric
05/2000

Therapy/Procedure

3Therapeutics
03/2010 - 04/2008
1Replacement Arthroplasty
04/2010